BRAINN: Brain Research and Integrative Neuroscience Network for COVID-19

脑研究和综合神经科学网络COVID-19（BRAINN）将推进塞浦路斯大学（UCY）的研究和创新能力，如在“扩大参与和加强ERA”工作计划中所示，通过与脑研究的三个先进合作伙伴，马斯特里赫特大学（UM），国王学院伦敦（KCL）和根特大学（UGent）。通过网络活动，培训和协调行动，BRAINN将开发一种创新的应用神经科学方法，以评估COVID-19对大脑健康的影响，并提高因COVID-19而患有精神健康和认知问题的患者的评估，诊断，预后和治疗标准。UM、KCL和UGent团队在神经影像学、无创神经刺激和数字化评估方法方面拥有世界知名的专业知识，拥有丰富的研究管理经验，并对COVID后研究充满兴趣。这些团队作为合作伙伴参与将提供所需的指导和培训，以互利的方式对神经科学研究进行重点和系统的方法，以提高UCY的研究形象，并加强UCY工作人员的研究管理和行政技能。BRAINN将使所有合作伙伴受益，因为评估和治疗方案的标准化将加快数据收集，并将保障网络的可持续性和未来扩展。通过跨学科研究和新方法和技术的开发，BRAINN将为个性化治疗做出贡献，将UCY和塞浦路斯带到科学前沿。此外，BRAINN将应对塞浦路斯近年来日益严重的人才流失挑战，并为减轻COVID-19造成的负担做出贡献。产生的知识和方法将超越BRAINN，因为它们将适用于影响大脑健康的其他条件，即使COVID-19被根除。

The Brain Research and Integrative Neuroscience Network for COVID-19 (BRAINN) will advance the research and innovation capacity of the University of Cyprus (UCY) as indicated in the ‘Widening Participation & Strengthening the ERA’ Work Programme, by twinning with three advanced partners in brain research, Maastricht University (UM), King’s College London (KCL), and Ghent University (UGent). Through networking activities, training and coordinated actions, BRAINN will develop an innovative applied neuroscience approach to characterise the effects of COVID-19 on brain health and to elevate the standards of assessment, diagnosis, prognosis, and treatment of patients with mental health and cognitive problems due to COVID-19. The UM, KCL and UGent teams have complementary world-renowned expertise in neuroimaging, non-invasive neurostimulation and digitalised assessment methods, extensive research management experience and active interest in post-COVID research. Engaging these teams as partners will provide the required mentoring and training towards a focused and systematic approach to neuroscience research in a mutually beneficial manner to raise the research profile of UCY, as well as strengthen the research management and administrative skills of UCY staff. BRAINN will benefit all partners, as the standardisation of assessment and treatment protocols will expedite data collection and will safeguard the sustainability and future expansion of the network. Through interdisciplinary research and development of novel methods and technologies, BRAINN will contribute to personalised treatments, bringing both UCY and Cyprus to the scientific forefront. Additionally, BRAINN will address the brain drain challenge that has increased in Cyprus over the recent years and contribute to the reduction in the burden created by COVID-19. The knowledge and methodologies produced will extend beyond BRAINN, since they will be applicable to other conditions affecting brain health, even when COVID-19 is eradicated.